Novo Nordisk has made its smart insulinpens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first ...
The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...